Avidity Partners Management LP Has $86.71 Million Holdings in Dianthus Therapeutics, Inc. $DNTH

Avidity Partners Management LP lowered its position in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 34.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,104,184 shares of the company’s stock after selling 1,100,000 shares during the quarter. Dianthus Therapeutics accounts for approximately 25.0% of Avidity Partners Management LP’s investment portfolio, making the stock its largest position. Avidity Partners Management LP’s holdings in Dianthus Therapeutics were worth $86,713,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Vanguard Group Inc. boosted its position in shares of Dianthus Therapeutics by 24.7% in the 4th quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock valued at $84,417,000 after purchasing an additional 406,254 shares during the period. Patient Square Capital LP acquired a new position in shares of Dianthus Therapeutics in the 3rd quarter valued at $4,919,000. UBS Group AG boosted its position in shares of Dianthus Therapeutics by 342.6% in the 4th quarter. UBS Group AG now owns 606,620 shares of the company’s stock valued at $24,999,000 after purchasing an additional 469,547 shares during the period. SG Americas Securities LLC acquired a new position in shares of Dianthus Therapeutics in the 4th quarter valued at $765,000. Finally, Fairmount Funds Management LLC boosted its position in shares of Dianthus Therapeutics by 22.2% in the 3rd quarter. Fairmount Funds Management LLC now owns 3,307,191 shares of the company’s stock valued at $130,138,000 after purchasing an additional 600,000 shares during the period. Institutional investors and hedge funds own 47.53% of the company’s stock.

Insider Transactions at Dianthus Therapeutics

In other Dianthus Therapeutics news, EVP Simrat Randhawa sold 26,530 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $90.62, for a total transaction of $2,404,148.60. Following the completion of the sale, the executive vice president directly owned 4,000 shares in the company, valued at approximately $362,480. This trade represents a 86.90% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Ryan Savitz sold 8,224 shares of the firm’s stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $89.84, for a total value of $738,844.16. Following the sale, the executive vice president directly owned 8,224 shares of the company’s stock, valued at $738,844.16. This trade represents a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 149,121 shares of company stock valued at $12,635,454 over the last 90 days. Corporate insiders own 3.02% of the company’s stock.

Dianthus Therapeutics Trading Up 7.4%

Shares of NASDAQ DNTH opened at $82.07 on Friday. Dianthus Therapeutics, Inc. has a one year low of $16.64 and a one year high of $96.50. The firm has a market capitalization of $4.49 billion, a PE ratio of -19.87 and a beta of 1.18. The business has a 50-day moving average price of $87.10 and a two-hundred day moving average price of $65.07.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($0.85) EPS for the quarter, topping analysts’ consensus estimates of ($1.07) by $0.22. Dianthus Therapeutics had a negative return on equity of 27.30% and a negative net margin of 12,998.50%.The firm had revenue of $0.46 million during the quarter, compared to analyst estimates of $0.40 million. Research analysts anticipate that Dianthus Therapeutics, Inc. will post -3.82 EPS for the current year.

Analyst Ratings Changes

A number of research firms recently weighed in on DNTH. Jefferies Financial Group set a $98.00 price target on Dianthus Therapeutics and gave the company a “buy” rating in a research report on Monday, March 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research report on Monday, April 20th. TD Cowen reiterated a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday. William Blair reiterated an “outperform” rating on shares of Dianthus Therapeutics in a research report on Monday, March 16th. Finally, Guggenheim reiterated a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $117.82.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.